



ASX ANNOUNCEMENT

16 November 2022

Share Purchase Plan closing date extended

16 November 2022 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) refers to the Share Purchase Plan (**SPP**) announced on 25 October 2022 and advises that the closing date for applications has been extended to **5.00pm (Melbourne time) on Wednesday, 30 November 2022**.

The Company has been made aware that many of its shareholders have experienced difficulties in either receiving materials due to postal delays or accessing the SPP online platform.

The extension has been granted to ensure that all eligible shareholders have an opportunity to participate in the SPP.

Shareholders who have already applied for shares under the SPP do not need to take any further action unless they wish to apply for additional shares, up to a maximum application amount of \$30,000, as referred to in the SPP offer documents released on 31 October 2022.

All other terms of the SPP remain the same.

An updated SPP timetable is below:

Event	Date
SPP Offer closes	5:00pm (Melbourne time) Wednesday, 30 November 2022
Completion announcement date (and notice of scale backs, if any)	Monday 5 December 2022
Allotment Date	Wednesday, 7 December 2022
Dispatch Holding Statements	Thursday, 8 December 2022

The above timetable is indicative only and subject to change at the discretion of the Company.

The Company welcomes the support it has received from shareholders for the SPP to date and looks forward to completing this important capital raise.

Authorised for release by the Company Secretary, Cann Group Limited.

For all media enquiries please contact:

Rhys Cohen
Senior Corporate Communications Manager
+61 449 679 095
rhys.cohen@canngrouplimited.com

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Deborah Ambrosini
CFO and Company Secretary
Cann Group Limited
+61 3 9095 7088
deborah.ambrosini@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouplimited.com | www.satipharm.com